J.K., C.C.C., K.A.V. and J.T.D. contributed equally to this work.
Article first published online: 14 SEP 2012
Copyright © 2012 UICC
International Journal of Cancer
Volume 132, Issue 6, pages 1475–1485, 15 March 2013
How to Cite
Kim, J., Coss, C. C., Barrett, C. M., Mohler, M. L., Bohl, C. E., Li, C.-M., He, Y., Veverka, K. A. and Dalton, J. T. (2013), Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen. Int. J. Cancer, 132: 1475–1485. doi: 10.1002/ijc.27794
Conflict of interest: All authors are either current or former employees of GTx Inc. GTx markets Fareston® (toremifene citrate) for the treatment of metastatic breast cancer in post menopausal women. Dr. Karen A. Veverka is currently (as of June 2011) employed by Novartis Pharmaceuticals Corporation.
- Issue published online: 24 JAN 2013
- Article first published online: 14 SEP 2012
- Accepted manuscript online: 23 AUG 2012 04:46AM EST
- Manuscript Accepted: 31 JUL 2012
- Manuscript Received: 19 JUN 2012
Additional Supporting Information may be found in the online version of this article.
|IJC_27794_sm_SuppFig1.ppt||61K||Supporting Information Figure 1.|
|IJC_27794_sm_SuppFig2.ppt||174K||Supporting Information Figure 2.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.